Skip To Main Content
Yingjun Chang on Muck Rack

Yingjun Chang

As seen in: Nature, Wiley Online Library, Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingjun

Contact Yingjun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ATRA improves megakaryopoiesis in immune thrombocytopenia through up-regulating the HIF-1α/SPHK2/S1P pathway

|
By Valdemar Priebe, Peter Sheridan Dodds, Mohammad A Saad, Qiu-Sha Huang, Jing XUE, Feng-Qi Liu, Qi Chen, Gaochao Zhang, Xue-yan Sun, Chencong Wang, Liping Yang, Yu Hou, Yueying Li, Qianfei Wang, Jun Peng, Ming Hai Hou, Xiaosu Zhao, Yuan Kong, Yingjun Chang, Xiangyu Zhao, Xiao-Jun Huang, Xiao-Hui Zhang
| Science Magazine Verified
Abstract Our previous clinical studies show that all-trans retinoic acid (ATRA) induces a sustained response in patients with immune thrombocytopenia (ITP). However, its mechanisms of action remain unclear. In this study, we observed disorganized cytoskeleton and impaired proplatelet formation (PPF) in megakaryocytes from patients with ITP. Metabolite profiling revealed reduced sphingosine 1-phosphate (S1P) levels in ITP.
Open in Who Shared Issue with article?

Alternative donors, particularly haploidentical donors, are safe and effective for elderly patients with adverse-risk AML: a multicenter TROPHY study

|
By Wenxuan Huo, Congxiao Zhang, Zhen Shang, Yingjun Chang, Jiong Hu, Ling Wang, Yu Wang, Chun Wang, Yi Yu, Linghui Xia, Hua Jin, Wei Shi, Yang Cao, Yanmin Zhao, Jia Chen, XiaoXia Hu, Xiaodong Mo, Chuanhe Jiang, Miaomaio Zhao, Jinyun Lai, Chuxian Zhao
| Nature Verified
Dear editor, Adverse-risk acute myeloid leukemia (AML) is one of the most life-threatening hematologic malignancies in adults [1], and allogeneic stem cell transplantation (allo-HSCT) is the standard consolidation therapy after achieving complete remission (CR) [2]. However, the incidence of AML increases with advancing age, with a median age at diagnosis ranging from 65 to 72 years [3].
Open in Who Shared Issue with article?

Is sex chromosome loss a predictive marker for outcome after sex-mismatched allogeneic hematopoietic stem cell transplantation?

|
By Lu Gao, Lin Feng, Xiaohui Zhang, Lanping Xu, Yu Wang, Yingjun Chang, Xiaojun Huang, Yueyun Lai
| Nature Verified
Abstract Sex chromosome loss (SCL) occasionally occurs after sex-mismatched allogeneic hematopoietic stem cell transplantation (allo-HSCT), but its clinical significance remains unclear. This retrospective study analyzed 78 patients who developed SCL after sex-mismatched HSCT, comprising 27 cases with initial-onset SCL (detected within first month post-transplant) and 51 cases with late-onset SCL (median onset time: 6.1 months; range: 2-73.1 months).
Open in Who Shared Issue with article?
See all 6 articles